Physician profile
Daniel B Fram
NPI 1770586471
$3,274.49
in general payments reported to CMS, 2019-2025
22 companies · $583 in 2025
The $583 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $281 · 2021: $643 · 2022: $878 · 2023: $282 · 2024: $116 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $636.49 | 2019-2025 | Avvigo Guidance System |
| Cardiovascular Systems INC. | $555.31 | 2020-2023 | Diamondback Coronary |
| Astrazeneca Pharmaceuticals Lp | $379.81 | 2019-2023 | Brilinta |
| Terumo Medical Corporation | $364.94 | 2021-2022 | |
| Edwards Lifesciences Corporation | $194.95 | 2019-2025 | |
| Chiesi USA, INC. | $151.89 | 2019-2025 | Kengreal |
| Medtronic, INC. | $134.39 | 2022-2025 | Corevalve Evolut R, Symplicity G3 |
| Acist Medical Systems, INC. | $131.08 | 2019-2022 | |
| Asahi Intecc USA, INC. | $125.00 | 2019 | |
| Abbott Laboratories | $124.59 | 2019-2025 | Coroflow, Nc Trek Neo, Cardiomems |
| Opsens INC. | $68.03 | 2019-2021 | |
| Shockwave Medical, INC | $67.89 | 2021-2025 | |
| Amgen INC. | $53.34 | 2019-2020 | |
| Angiodynamics, INC. | $46.98 | 2025 | Alphavac |
| E.R. Squibb & Sons, L.L.C. | $46.74 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $41.83 | 2022-2025 | Mynx Control Venous |
| Biotronik INC. | $39.64 | 2019-2022 | |
| Ge Healthcare | $30.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $26.70 | 2020-2021 | |
| Penumbra, INC. | $20.25 | 2023 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.82 | 2024 | Jardiance |
| Abiomed | $15.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.